NovoCure Limited announced that it will receive $400 million in a round of funding on May 2, 2024. The committed capital will be issued in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at discretion and subject to certain milestones, through March 31, 2026.

On the same day, the company received $100 million in its first tranche. The transaction included participation from new lender Pharmakon Advisors, LP. The company issued senior secured credit facility.